Gastric Cancer Induced by PPARδ Activation
Author Information
Author(s): Claire B. Pollock, Olga Rodriguez, Philip L. Martin, Chris Albanese, Xin Li, Levy Kopelovich, Robert I. Glazer
Primary Institution: Lombardi Comprehensive Cancer Center, Georgetown University
Hypothesis
Activation of PPARδ by the agonist GW501516 promotes gastric tumorigenesis.
Conclusion
The study demonstrates that PPARδ activation leads to rapid development of highly metastatic gastric tumors in a mouse model.
Supporting Evidence
- 12 out of 15 mice developed gastric tumors after treatment with GW501516 and DMBA.
- Rapid tumor growth was observed as early as 19 days after starting the GW501516 diet.
- Gene expression analysis showed increased inflammatory markers in tumors.
Takeaway
When mice were given a special drug after a cancer-causing substance, they quickly developed stomach tumors. This helps scientists understand how stomach cancer can grow.
Methodology
Mice were treated with DMBA and then given the PPARδ agonist GW501516 to observe tumor development.
Limitations
The model produces squamous cell carcinomas from the forestomach rather than the more common adenocarcinomas seen in human gastric cancer.
Participant Demographics
Female FVB mice, six weeks old.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website